REFRACTORY T-CELL NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY T-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY T-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY T-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Combination therapy shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis phase II trial tested whether combining the immunotherapy drug pembrolizumab (Keytruda) with targeted radiation therapy could help patients whose non-Hodgkin lymphoma had returned or stopped responding to treatment. Seventeen adults with aggressive lymphoma types received bo…
Matched conditions: REFRACTORY T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug combo shows promise for Tough-to-Treat lymphomas
Disease control CompletedThis phase 1 trial tested the safety and best dose of olaparib when added to high-dose chemotherapy for 50 patients with lymphomas that returned or didn't respond to treatment. All patients were scheduled for a stem cell transplant. The goal was to see if the combination could wo…
Matched conditions: REFRACTORY T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC